Pharmacokinetics of sunitinib in hemodialysis.
Izzedine
H
H
Etienne-Grimaldi
M C
MC
Renée
N
N
Vignot
S
S
Milano
G
G
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D006435:Renal Dialysis / Q000379:methods*; D051437:Renal Insufficiency / Q000209:etiology / Q000628:therapy; D000077210:Sunitinib; D055815:Young Adult
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib